Professor Florence Cymbalista, MD, PhD - Transforming Care With BTK Inhibitors in CLL: New Insights on Therapy Selection, Safety, and Agent Sequencing Across the Treatment Continuum

1:27:09
 
Share
 

Manage episode 267165478 series 1058605
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/QHM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity features insights from leading clinicians on the evidence that links the underlying mechanistic principles of Bruton tyrosine kinase inhibition with lessons arising from major clinical studies of first- and second-generation BTK agents in the chronic lymphocytic leukemia (CLL) setting. Upon completion of this activity, participants should be better able to: Discuss the implications of mechanistic and selectivity difference among first- and second-generation BTK inhibitors in the context of CLL care, Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL and in patients unable to tolerate BTK inhibitor therapy, Manage the unique spectrum of toxicity associated with the use of BTK inhibitors in patients with CLL.

260 episodes